ID25592A - Mikropartikel lipofilik yang mengandung obat protein atau anti gen formulasi yang terdiri dari mikropartikel tersebut - Google Patents

Mikropartikel lipofilik yang mengandung obat protein atau anti gen formulasi yang terdiri dari mikropartikel tersebut

Info

Publication number
ID25592A
ID25592A IDW20001816A ID20001816A ID25592A ID 25592 A ID25592 A ID 25592A ID W20001816 A IDW20001816 A ID W20001816A ID 20001816 A ID20001816 A ID 20001816A ID 25592 A ID25592 A ID 25592A
Authority
ID
Indonesia
Prior art keywords
microparticles
lipofilic
contain drugs
anti gen
formulation consist
Prior art date
Application number
IDW20001816A
Other languages
English (en)
Indonesian (id)
Inventor
Myung-Jin Kim
Sun-Jin Kim
Kyu-Chan Kwon
Joon Kim
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019990001232A external-priority patent/KR100329336B1/ko
Priority claimed from KR1019990059776A external-priority patent/KR100359252B1/ko
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of ID25592A publication Critical patent/ID25592A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IDW20001816A 1999-01-18 2000-01-14 Mikropartikel lipofilik yang mengandung obat protein atau anti gen formulasi yang terdiri dari mikropartikel tersebut ID25592A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1019990001232A KR100329336B1 (ko) 1999-01-18 1999-01-18 히아루론산을 이용한 단백질 약물의 서방성 미세 입자 제형
KR1019990059776A KR100359252B1 (ko) 1999-12-21 1999-12-21 항원을 포함하는 고체상 미세입자 및 이를 포함하는 제제

Publications (1)

Publication Number Publication Date
ID25592A true ID25592A (id) 2000-10-19

Family

ID=26634599

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001816A ID25592A (id) 1999-01-18 2000-01-14 Mikropartikel lipofilik yang mengandung obat protein atau anti gen formulasi yang terdiri dari mikropartikel tersebut

Country Status (20)

Country Link
EP (2) EP1071407B1 (pt)
JP (1) JP3802348B2 (pt)
CN (1) CN1142772C (pt)
AR (1) AR043272A1 (pt)
AU (1) AU751200B2 (pt)
BG (1) BG65233B1 (pt)
BR (1) BR0004152A (pt)
CA (1) CA2324403C (pt)
DK (1) DK1071407T3 (pt)
ES (1) ES2505696T3 (pt)
HK (1) HK1036415A1 (pt)
HU (1) HUP0101040A3 (pt)
ID (1) ID25592A (pt)
IL (1) IL138468A0 (pt)
MY (1) MY125541A (pt)
NZ (1) NZ506975A (pt)
PL (1) PL200954B1 (pt)
TR (1) TR200002683T1 (pt)
TW (1) TWI260988B (pt)
WO (1) WO2000041682A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
AU2006201100B2 (en) * 1999-09-21 2009-09-24 Jagotec Ag Surface modified particulate compositions of biologically active substances
CN1174741C (zh) * 1999-09-21 2004-11-10 Rtp药品公司 生物活性物质的表面改性微粒组合物
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
WO2001093837A2 (en) * 2000-06-08 2001-12-13 Eli Lilly And Company Protein powder for pulmonary delivery
US6998393B2 (en) * 2000-06-23 2006-02-14 Biopharm Solutions, Inc. Aquespheres, their preparation and uses thereof
EP1420818B1 (en) * 2001-07-26 2018-11-21 Otago Innovation Limited Antigenic compositions
JP4683319B2 (ja) * 2003-02-19 2011-05-18 武田薬品工業株式会社 徐放性製剤用の分散剤
US20060088595A1 (en) * 2003-02-19 2006-04-27 Naoki Asakawa Dispersant for sustained release preparations
WO2005084637A2 (en) * 2004-02-13 2005-09-15 Nod Pharmaceuticals, Inc. Particles comprising a core of calcium phosphate nanoparticles, a biomolecule and a bile acid, methods of manufacturing, therapeutic use thereof
WO2005120484A1 (ja) * 2004-06-09 2005-12-22 Kurume University グレリンの生理学的機能のレギュレーター
KR100729954B1 (ko) * 2004-12-01 2007-06-20 주식회사 엘지생명과학 Ｓｅｃ１ 변이 단백질의 제형 및 그것의 제형화 방법
CA2621786A1 (en) 2005-08-29 2007-03-08 Tuo Jin Polysaccharide microparticles containing biological agents: there preparation and applications
EP1976551A4 (en) * 2005-12-23 2009-12-30 Altus Pharmaceuticals Inc COMPOSITIONS COMPRISING COMPLEX PROTEIN CRYSTALS BY POLYCATIONS AND PROCESSING METHOD THEREOF
FR2904219B1 (fr) * 2006-07-28 2010-08-13 Flamel Tech Sa Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant
CN101618213B (zh) * 2008-07-03 2013-01-23 武汉生物制品研究所有限责任公司 麻疹腮腺炎乙型脑炎联合减毒活疫苗及其制备方法
AU2009302111A1 (en) * 2008-10-08 2010-04-15 Immune Solutions Limited Oral vaccines for producing mucosal immunity
WO2014206857A1 (en) * 2013-06-28 2014-12-31 Universitat Autonoma De Barcelona Oil-in-water formulations of mycobacterium and uses thereof
CN103923881B (zh) * 2013-08-09 2016-04-06 北京科兴生物制品有限公司 甲肝病毒单克隆抗体及其应用
KR20160132494A (ko) 2014-04-03 2016-11-18 베링거잉겔하임베트메디카인코퍼레이티드 돼지 유행성 설사 바이러스 백신
GB201716419D0 (en) 2017-10-06 2017-11-22 Univ Central Lancashire Solid composition
CA3155131A1 (en) 2019-09-23 2021-04-01 Dds Research Inc. Lipid vesicle compositions with penetration enhancing agents
CN112933044A (zh) * 2020-12-17 2021-06-11 太阳雨林（厦门）生物医药有限公司 一种用于恶性肿瘤治疗的载药油制剂及制备方法和应用
CN112961221B (zh) * 2021-02-28 2022-05-17 长春祈健生物制品有限公司 一种水痘-带状疱疹病毒糖蛋白e胞外区蛋白的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
JPH01287041A (ja) 1988-05-13 1989-11-17 Rooman Kogyo:Kk 徐放性製剤
JP2513276B2 (ja) 1988-06-10 1996-07-03 日本電気株式会社 位相同期ル―プ
US5416017A (en) 1990-05-18 1995-05-16 The Scripps Research Institute Cholera toxin gene regulated by tissue-specific promoters
DE4107153A1 (de) * 1991-03-06 1992-09-10 Gregor Cevc Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
EP0485143B1 (en) * 1990-11-06 1997-12-17 Instituto Nacional De Engenharia E Tecnologia Industrial Liposomal compositions and processes for their production
WO1992014449A1 (en) * 1991-02-20 1992-09-03 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
PT726761E (pt) * 1993-11-03 2001-07-31 Isomed Inc Composicoes farmaceuticas que microparticulas na forma de micelios
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
KR100201352B1 (ko) 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
CA2266622C (en) 1996-09-27 2006-08-15 Hyal Pharmaceutical Corporation Hyaluronic drug delivery system
US6096291A (en) 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
WO2002009674A2 (en) * 2000-07-28 2002-02-07 Inhale Therapeutic Systems, Inc. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds

Also Published As

Publication number Publication date
ES2505696T3 (es) 2014-10-10
NZ506975A (en) 2004-01-30
TWI260988B (en) 2006-09-01
CN1142772C (zh) 2004-03-24
CA2324403C (en) 2005-12-13
HK1036415A1 (en) 2002-01-04
BG104742A (en) 2001-07-31
JP2002534459A (ja) 2002-10-15
AU3080500A (en) 2000-08-01
JP3802348B2 (ja) 2006-07-26
EP2481401A1 (en) 2012-08-01
BR0004152A (pt) 2000-11-21
TR200002683T1 (tr) 2000-12-21
EP1071407A4 (en) 2009-05-20
DK1071407T3 (da) 2014-10-20
PL200954B1 (pl) 2009-02-27
HUP0101040A3 (en) 2005-11-28
PL342967A1 (en) 2001-07-16
EP1071407A1 (en) 2001-01-31
CA2324403A1 (en) 2000-07-20
WO2000041682A1 (en) 2000-07-20
HUP0101040A2 (hu) 2001-08-28
BG65233B1 (bg) 2007-09-28
AR043272A1 (es) 2005-07-27
CN1293568A (zh) 2001-05-02
EP1071407B1 (en) 2014-07-23
IL138468A0 (en) 2001-10-31
AU751200B2 (en) 2002-08-08
MY125541A (en) 2006-08-31

Similar Documents

Publication Publication Date Title
ID25592A (id) Mikropartikel lipofilik yang mengandung obat protein atau anti gen formulasi yang terdiri dari mikropartikel tersebut
CY2014003I1 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
PT1207867E (pt) Formas de administracao farmaceuticas orais retardadas contendo tramadol
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
PT1221917E (pt) Dispositivo para ministrar medicamentos
EE200200349A (et) Antiprogestiinsete omadustega ravimite manustamise vahendid
DE602004014283D1 (de) System zur Einführung von mehreren Medizinprodukten
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
PT1221918E (pt) Administracao de drogas sub-tenon
IS5245A (is) Lyfjablanda úr ómeprasól
HUP0400096A2 (hu) Biszfoszfonátok gyógyászati alkalmazása
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
EE200100259A (et) Moksifloksatsiini farmatseutiline preparaat
NO20033384L (no) Farmasoytisk formulering
NO20033785D0 (no) Farmasöytisk formulering
GB0202633D0 (en) Stabilization of protein preparations
ID25535A (id) Komposisi batangan yang terdiri dari tetesan-tetesan pelunak yang terperangkap terdispersi padanya
NO20044916L (no) Preparater av sulfinylacetamid
NO20035627D0 (no) Farmasöytisk formulering
DE60232290D1 (de) Kontrollierte Auflösung von Wirkstoffen
HUP0600778A3 (en) Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
PT1239862E (pt) Preparacao farmaceutica contendo citostaticos e aceitadores de electroes para o tratamento de cancro
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20022101D0 (no) Peptider for behandling av erektil dysfunksjon